- $74.06m
- $33.70m
- 15
- 36
- 56
- 28
Annual income statement for Medicinova, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 4.04 | 0 | 1 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 14.2 | 14.3 | 14.6 | 10.9 | 12.7 |
| Operating Profit | -14.2 | -10.2 | -14.6 | -9.9 | -12.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.9 | -10.1 | -14.1 | -8.57 | -11 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.9 | -10.1 | -14.1 | -8.57 | -11 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.9 | -10.1 | -14.1 | -8.57 | -11 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.9 | -10.1 | -14.1 | -8.57 | -11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.312 | -0.209 | -0.287 | -0.175 | -0.225 |